Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

Abstract

PROMIS is funded by the UK Government Department of Health, National Institute of Health Research-Health Technology Assessment Programme, (Project number 09/22/67). This project is also supported and partly funded by UCLH/UCL Biomedical Research Centre and The Royal Marsden and Institute for Cancer Research Biomedical Research Centre and is coordinated by the Medical Research Council Clinical Trials Unit (MRC CTU) at UCL. It is sponsored by University College London (UCL).

Current Utilization and Acceptance of Multiparametric MRI in the Diagnosis of Prostate Cancer. A Regional Survey

“…Only 41 % of respondents were advised by their physician about the possibility of an MRI and MRI-guided biopsy after a negative TRUS biopsy, despite higher detection rates, reduced histological upgrading, and the possibility to rule out clinically significant tumors; in comparison to TRUS-GB, no increased side effects or complications have been demonstrated, and patients have shown good acceptance of the procedure [28,29].…”

Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance

“…5 The diagnostic inaccuracies of biopsy and traditional risk stratification measures create a need for improved methods to identify men at low risk of progression who may avoid initial therapy, a limitation that is being addressed by the growing use of genomic biomarkers [6][7][8] and multiparametic magnetic resonance imaging as diagnostic tools. 9,10 The OncotypeDX Genomic Prostate Score (GPS) TM , is a 17-gene quantitative RT PCR assay of selected genes from four cancer related molecular pathways (androgen signaling, cellular organization, stromal response, and cellular proliferation) 11 that has been analytically 11 and clinically 12,13 validated when measured on prostate biopsies to predict the presence of adverse pathology (GrdGrp 3 or higher or non-organ confined disease), as well as time to biochemical recurrence and metastasis.…”

A multidisciplinary group for prostate cancer management: A single institution experience

“…In fact, MP-MRI allows to detect more cases of clinically significant cancer compared with the standard TRUS-biopsy (15), avoiding a primary biopsy and diagnosis of some clinically insignificant cancers.…”